Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Nanoviricides - The Other Board -- Ignore unavailable to you. Want to Upgrade?

To: drkaz who wrote (891)	7/17/2018 4:06:13 PM
From: Its_lose_not_loose	Read Replies (1) \| Respond to of 1010

gives me hours of entertainment. I'm sorry your life is so dull that we would provide that much amusement...

To: drkaz who wrote (891)	7/23/2018 4:33:23 PM
From: arvitar	Read Replies (1) \| Respond to of 1010

Mostly appears to be sour grapes by investors who are attempting to blame the company and it's principles for losses because the drug failed in its Phase III, despite having appeared to be good after it's Phase II trials. EVERY class action lawsuit is sour grapes over lost money, you freaking putz! That doesn't mean the fraud allegations are without merit. A law firm who specializes in suing companies for this type of thing certainly doesn't think so. Prospective investors aren't going to consider a company run by a CEO without any record of success, who's embroiled in a lawsuit for fraud. There are too many opportunities that don't have this baggage. Not that they were any more attracted by NNVC being a piggy bank used by Diwan to fund Theracour.